平消胶囊联合高强度聚焦超声治疗子宫肌瘤的临床疗效
|
摘要
目的探讨平消胶囊联合高强度聚焦超声治疗子宫肌瘤的临床疗效。方法回顾性分析2016年8月至2018年2月收治的90例子宫肌瘤患者的临床资料。按照治疗方法的不同分为研究组和对照组,各45例。对照组采用高强度聚焦超声治疗,研究组采用平消胶囊联合高强度聚焦超声治疗。治疗6个月后,对比两组的疗效及两组治疗前后CD3、CD4、CD4/CD8、CD56的水平,检测两组的病灶体积、子宫体积变化。结果研究组的总有效率比对照组高(93.37%vs 80.00%,P<0.05);研究组治疗后的CD3、CD4、CD4/CD8、CD56明显升高(P<0.05);治疗后,研究组的CD3、CD4、CD4/CD8、CD56比对照组高(P<0.05);两组治疗后的病灶体积、子宫体积明显降低(P<0.05);治疗后,研究组的病灶体积[(39.71±10.47)cm~3vs(49.12±12.35)cm~3]、子宫体积[(109.35±15.28)cm~3vs(121.70±17.06)cm~3]低于对照组(P<0.05)。结论平消胶囊能进一步提高高强度聚焦超声治疗子宫肌瘤的疗效,改善免疫功能。
Objective To investigate the clinical effect of Pingxiao Capsule combined with high-intensity focused ultrasound in the treatment of uterine leiomyoma.Methods The clinical data of 90 patients with uterine leiomyoma who received treatment from August 2016 to February 2018 was retrospectively analyzed,and all the patients were divided into control group and study group.The control group was treated with high-intensity focused ultrasound,and the study group was treated with Pingxiao capsule combined with high-intensity focused ultrasound.Results The total efficacy rate in study group was significantly higher than that in control group(93.38% vs 80.00%,P<0.05).The CD3,CD4,CD4/CD8 and CD56 were significantly higher in study group after the treatment,and they were higher in study group than those in control group(all P<0.05).After the treatment,the volume of lesion and uterus decreased significantly in both group(all P<0.05).Compared with control group,the volume of lesion and uterus were smaller in study group after the treatment[(39.71±10.47)cm~3 vs(49.12±12.35)cm~3,P<0.05;(109.35±15.28) cm~3 vs(121.70±17.06) cm~3,P<0.05].Conclusion Pingxiao capsule can further improve the efficacy of high-intensity focused ultrasound in the treatment of uterine fibroids and improve the immune function.
Objective To investigate the clinical effect of Pingxiao Capsule combined with high-intensity focused ultrasound in the treatment of uterine leiomyoma.Methods The clinical data of 90 patients with uterine leiomyoma who received treatment from August 2016 to February 2018 was retrospectively analyzed,and all the patients were divided into control group and study group.The control group was treated with high-intensity focused ultrasound,and the study group was treated with Pingxiao capsule combined with high-intensity focused ultrasound.Results The total efficacy rate in study group was significantly higher than that in control group(93.38% vs 80.00%,P<0.05).The CD3,CD4,CD4/CD8 and CD56 were significantly higher in study group after the treatment,and they were higher in study group than those in control group(all P<0.05).After the treatment,the volume of lesion and uterus decreased significantly in both group(all P<0.05).Compared with control group,the volume of lesion and uterus were smaller in study group after the treatment[(39.71±10.47)cm~3 vs(49.12±12.35)cm~3,P<0.05;(109.35±15.28) cm~3 vs(121.70±17.06) cm~3,P<0.05].Conclusion Pingxiao capsule can further improve the efficacy of high-intensity focused ultrasound in the treatment of uterine fibroids and improve the immune function.
引文
[1] 封全灵,张倩,刘弘扬,等.子宫肌瘤发病孕激素相关危险因素病例对照研究[J].中国妇幼保健,2016,31(2):241-243.
[2] 雍敏,蒋静,陈燕,等.高强度聚焦超声治疗子宫肌瘤短时期非计划妊娠结局的回顾性分析[J].中国超声医学杂志,2018,34(2):171-174.
[3] 杨辉.平消胶囊治疗乳腺增生并子宫肌瘤的临床观察[J].现代肿瘤医学,2014,22(7):1656-1658.
[4] 乐杰.妇产科学[M].北京:人民卫生出版社,2008.
[5] 郑筱萸.中药新药临床研究指导原则:试行[M].北京:中国医药科技出版社,2002.
[6] 常悦,钱景锋,高丽军,等.有生育要求的子宫肌瘤患者的治疗进展[J].实用妇产科杂志,2018,34(3):186-189.
[7] 徐小娟,刘晓芳,何佳.高强度聚焦超声治疗子宫肌瘤2年随访结果分析[J].中国实用妇科与产科杂志,2018,34(2):214-218.
[8] 王振骏,蒋静,陈燕,等.高强度聚焦超声对子宫肌瘤患者围手术期免疫功能的影响[J].中国超声医学杂志,2018,34(2):174-177.
[9] 邢峰丽,封若雨,孙芳,等.浅议子宫肌瘤的中医辨证分型[J].环球中医药,2017,10(7):840-842.
[10] 向丽,曹丽蓉,王中显.温肾化痰祛瘀方联合高强度聚焦超声治疗子宫肌瘤的临床疗效[J].中国临床研究,2018,31(9):1281-1284.
[11] 危丽华.平消胶囊联合米非司酮治疗子宫肌瘤的临床研究[J].现代药物与临床,2018(2):303-307.
[12] 王娟,岳正刚,董明芝,等.平消胶囊的抗肿瘤作用及其机制研究[J].中华中医药杂志,2017,32(10):4658-4663.
[13] 欧阳晨捷.子宫肌瘤的发病机制研究进展[J].中南医学科学杂志,2016,44(6):708-711.
[14] 李玉,韩娇玲,张震,等.CD3和CD28单克隆抗体联合作用对CIK细胞及其亚群增殖及功能的影响[J].中国肿瘤生物治疗杂志,2016,23(2):255-260.
[15] 刘珈杞,刘耀华,陈鑫,等.CD4+CD25+Foxp3+Treg细胞调控肿瘤免疫抑制微环境的研究进展[J].实用肿瘤学杂志,2016,30(6):555-559.
[16] 王志华.NK细胞抗肿瘤临床转化研究进展[J].中国肿瘤生物治疗杂志,2016,23(3):419-426.
[2] 雍敏,蒋静,陈燕,等.高强度聚焦超声治疗子宫肌瘤短时期非计划妊娠结局的回顾性分析[J].中国超声医学杂志,2018,34(2):171-174.
[3] 杨辉.平消胶囊治疗乳腺增生并子宫肌瘤的临床观察[J].现代肿瘤医学,2014,22(7):1656-1658.
[4] 乐杰.妇产科学[M].北京:人民卫生出版社,2008.
[5] 郑筱萸.中药新药临床研究指导原则:试行[M].北京:中国医药科技出版社,2002.
[6] 常悦,钱景锋,高丽军,等.有生育要求的子宫肌瘤患者的治疗进展[J].实用妇产科杂志,2018,34(3):186-189.
[7] 徐小娟,刘晓芳,何佳.高强度聚焦超声治疗子宫肌瘤2年随访结果分析[J].中国实用妇科与产科杂志,2018,34(2):214-218.
[8] 王振骏,蒋静,陈燕,等.高强度聚焦超声对子宫肌瘤患者围手术期免疫功能的影响[J].中国超声医学杂志,2018,34(2):174-177.
[9] 邢峰丽,封若雨,孙芳,等.浅议子宫肌瘤的中医辨证分型[J].环球中医药,2017,10(7):840-842.
[10] 向丽,曹丽蓉,王中显.温肾化痰祛瘀方联合高强度聚焦超声治疗子宫肌瘤的临床疗效[J].中国临床研究,2018,31(9):1281-1284.
[11] 危丽华.平消胶囊联合米非司酮治疗子宫肌瘤的临床研究[J].现代药物与临床,2018(2):303-307.
[12] 王娟,岳正刚,董明芝,等.平消胶囊的抗肿瘤作用及其机制研究[J].中华中医药杂志,2017,32(10):4658-4663.
[13] 欧阳晨捷.子宫肌瘤的发病机制研究进展[J].中南医学科学杂志,2016,44(6):708-711.
[14] 李玉,韩娇玲,张震,等.CD3和CD28单克隆抗体联合作用对CIK细胞及其亚群增殖及功能的影响[J].中国肿瘤生物治疗杂志,2016,23(2):255-260.
[15] 刘珈杞,刘耀华,陈鑫,等.CD4+CD25+Foxp3+Treg细胞调控肿瘤免疫抑制微环境的研究进展[J].实用肿瘤学杂志,2016,30(6):555-559.
[16] 王志华.NK细胞抗肿瘤临床转化研究进展[J].中国肿瘤生物治疗杂志,2016,23(3):419-426.